Weekly丨Advancing AI drug discovery & longevity science | Insilico Medicine at three premier global summits in early October
Meeting Announcement
Updates every hour. Last Updated: 22-Oct-2026 12:17 ET (22-Oct-2026 16:17 GMT/UTC)
October 6–7 | Abu Dhabi
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to speak at the AI Everything Abu Dhabi summit.October 7–9 | Yokohama, Japan
Insilico Medicine will make an appearance at BioJapan 2026, held from October 7 to 9 at PACIFICO Yokohama, at Booth D74.October 7–11 | San Francisco
Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine, has been invited to attend the Abundance Longevity Trip, founded by Dr. Peter Diamandis.Nationwide Duke-NUS study finds asthma-related emergency visits rise within two days of increases in PM2.5, underscoring the importance of early precautions during periods of poorer air quality.
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced the nomination of ISM1354, an AI-driven novel small molecule preclinical candidate (PCC) targeting GIPR, for the potential intervention of obesity, as well as obesity-related disorders including type 2 diabetes, with the potential to expand into cardiovascular diseases in regulating obesity-associated heart failure and more. Notably, in January of this year, Insilico announced the nomination of another GIPR antagonist, ISM0676, which demonstrated up to a 31.3% weight loss when used in combination with Semaglutide in humanized mouse models. In comparison, the newly nominated PCC maintains robust weight-loss efficacy while delivering further improvements in pharmacokinetic and safety profiles, while retaining its favorable drug-like properties.
From sloths to birds, vertebrates rely on insects for a wide array of purposes, including food, shelter, and medicine, according to an international paper co-authored by faculty at Binghamton University, State University of New York.
Even after receiving guideline‑directed treatment for acute coronary syndrome, many patients face persistent residual cardiovascular risk and repeated ischemic events. This narrative review published in Cardiology Discovery synthesizes recent clinical evidence to build a practical management framework for clinicians caring for acute coronary syndrome survivors. The authors organize residual risks into non-culprit lesion instability, lipid‑related, inflammatory, thrombotic and modifiable lifestyle‑driven categories, and summarize available pharmacologic and non‑pharmacologic interventions for each risk domain. The work supports personalized risk assessment to guide tailored secondary prevention plans. As a narrative review, it does not generate original clinical trial data and requires real‑world studies to validate the proposed clinical workflows.
The research team from National University of Defense Technology systematically described the memory efficiency issues in the training process of large language models (LLMs) with Transformer architecture for scientific fields. As the scale of models continues to expand, memory requirements have become a key bottleneck restricting their applications in scientific fields such as biology, medicine, chemistry, and meteorology. The article systematically reviewed memory-efficient pre-training technologies at the algorithm level, system level, and software-hardware collaborative optimization, and combined with the AlphaFold 2 case, demonstrated how customized memory optimization methods can reduce storage overhead while maintaining prediction accuracy.
Coronary artery disease remains the top global cause of death, yet standard angiography cannot visualize dangerous artery plaque, creating gaps for guiding percutaneous coronary intervention. This narrative review synthesizes 10 years of human studies, clinical trials and consensus documents covering established and emerging intravascular imaging plus computational tools. Hybrid catheter systems have completed first‑in‑human testing, while artificial‑intelligence plaque analysis delivers diagnostic accuracy comparable to expert readers. These technologies enable combined anatomical, compositional and functional vessel assessment, though broad clinical roll‑out still requires standardized validation and streamlined workflow integration.